ZOSANO PHARMA, INC. TO PRESENT AT BIO INVESTOR FORUM
Fremont, Calif. – October 23, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications, announced today that John Vuko, Chief Financial Officer of Zosano will present at the 7th annual BIO Investor Forum. Mr. Vuko will provide an update on the company’s progress. He will highlight the key features of its proprietary transdermal delivery technology as well as the recent Phase 2 results of its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, being developed as an alternative to daily injections.
The presentation will be delivered at the Palace Hotel in San Francisco, Calif., on Thursday October 30th at 1:45 PM PST. A copy of the presentation will be available on Zosano web site at www.zosanopharma.com following the meeting.
About Zosano Pharma, Inc.
Zosano Pharma, Inc. is a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications. Its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, is being developed as an alternative to daily injections and has strong phase 2 study results. Zosano’s transdermal delivery technology is capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin’s outer layer and ensuring significant therapeutic effect. This proven proprietary technology offers several key benefits, including efficacy and safety comparable to approved injectables, needle-free delivery, a self administered patch, rapid onset of action and room temperature storage. Zosano’s transdermal delivery technology has been clinically tested in over 400 patients with four different peptides and a vaccine. Zosano aims to develop products both independently and through strategic licensing and co-development arrangements. Founded in 2006 as an ALZA Corporation spin-out led by Nomura Phase4 Ventures, Zosano is funded by New Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments. For more information, please visit www.zosanopharma.com.